Svar Life Science

May 3, 2024

EDITORIAL ARTICLE: Developing a Customizable Complement-Dependent Cytotoxicity Assay

In this Editorial Article, cell-engineering experts and bioassay experts at Svar Life Science delve into the nuances of developing a CDC assay that goes beyond pure interaction and truly reflects cell lysis

The article also presents how this advanced engineering platform works and how it enables the design and construction of complex and sophisticated components. The possibilities regarding the potential number of target combinations are endless!

May 3, 2024

EDITORIAL ARTICLE: Developing a Customizable Complement-Dependent Cytotoxicity Assay

In this Editorial Article, cell-engineering experts and bioassay experts at Svar Life Science delve into the nuances of developing a CDC assay that goes beyond pure interaction and truly reflects cell lysis

The article also presents how this advanced engineering platform works and how it enables the design and construction of complex and sophisticated components. The possibilities regarding the potential number of target combinations are endless!

In the dynamic landscape of therapeutic antibodies, assessing Complement-Dependent Cytotoxicity (CDC) is crucial, yet existing tools face limitations, failing to reveal true cell lysis. Svar R&D teams in Paris and Malmö combined their expertise to address this need.

This collaboration between cell engineering and analytical experts resulted in a robust cell-based assay that truly shows cell lysis. The new development has been met with positive feedback from customers who have tested the platform.

Download this exclusive interview to learn about this innovative tool’s molecular and analytical nuances and how it can empower and streamline your antibody development.

 

Please complete the form to access the white paper